Sugi Predict

Sugi Predict / Compounds / SCHEMBL1655753

SCHEMBL1655753

SCHEMBL1655753

Nc1ccc2[nH]c(-c3ccc(-c4nc5cc(N)ccc5[nH]4)cc3)nc2c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 9/20 0.73
▸ KMT2A Q03164 9/20 0.73
▸ RXFP1 Q9HBX9 3/20 0.73
▸ CACNA1B Q00975 2/20 0.73
▸ APBA1 Q02410 2/20 0.73
▸ ALDH1A1 P00352 11/20 0.71
▸ SMN1; SMN2 Q16637 11/20 0.71
▸ MAPT P10636 10/20 0.71
▸ NPC1 O15118 10/20 0.71
▸ RAB9A P51151 9/20 0.71
▸ KDM4E B2RXH2 8/20 0.71
▸ GAA P10253 7/20 0.71
▸ GLA P06280 4/20 0.71
▸ GFER P55789 4/20 0.71
▸ RECQL P46063 2/20 0.71
▸ HPGD P15428 9/20 0.67
▸ POLB P06746 8/20 0.67
▸ HSD17B10 Q99714 5/20 0.67
▸ USP2 O75604 4/20 0.67
▸ NFKB1 P19838 3/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30533210 1.00 MEN1 (0.73) MEN1KMT2ARXFP1CACNA1BAPBA1
SCHEMBL30307784 0.98 ALDH1A1 (0.74) MEN1KMT2ARXFP1CACNA1BAPBA1
SCHEMBL159873 0.98 ALDH1A1 (0.74) MEN1KMT2ARXFP1CACNA1BAPBA1
SCHEMBL8769051 0.98 MEN1 (0.71) MEN1KMT2ARXFP1CACNA1BAPBA1
SCHEMBL28312335 0.98 ALDH1A1 (0.74) MEN1KMT2ARXFP1CACNA1BAPBA1
SCHEMBL10002475 0.95 ALDH1A1 (0.71) MEN1KMT2ARXFP1CACNA1BAPBA1
SCHEMBL15443982 0.93 MEN1 (0.87) MEN1KMT2ARXFP1CACNA1BAPBA1
SCHEMBL31289476 0.92 ALDH1A1 (0.71) MEN1KMT2ARXFP1CACNA1BAPBA1
SCHEMBL31289511 0.92 MEN1 (0.63) MEN1KMT2ARXFP1CACNA1BAPBA1
SCHEMBL8472844 0.92 MEN1 (0.63) MEN1KMT2ARXFP1CACNA1BAPBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710442-A2 BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME The Scripps Research Institute (US) 2020-09-23 — — EP claimed
US-20190152924-A1 BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2019-05-23 — — US claimed
EP-4493638-A1 PHOTOALIGNING MATERIALS Rolic Technologies AG (CH) 2025-01-22 — — EP disclosed
CN-118027412-A Photo-alignment material 罗利克技术有限公司 2024-05-14 — — CN disclosed
WO-2023174773-A1 PHOTOALIGNING MATERIALS Rolic Technologies AG (CH) 2023-09-21 — — WO disclosed
CN-116444794-A Benzimidazolyl-containing polyimide, and preparation method and application thereof 中广核研究院有限公司 2023-07-18 — — CN disclosed
US-11634544-B2 Photoaligning materials Rolic Technologies AG (CH) 2023-04-25 — — US disclosed
CN-108912011-B Photoalignment material 罗立克科技股份公司 2021-09-24 — — CN disclosed
US-10961202-B2 Bis-benzimidazole compounds and methods of using the same THE SCRIPPS RESEARCH INSTITUTE (US) 2021-03-30 — — US disclosed
US-10961202-B2 Bis-benzimidazole compounds and methods of using the same THE SCRIPPS RESEARCH INSTITUTE (US) 2021-03-30 — — US disclosed
EP-3710442-A2 BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME The Scripps Research Institute (US) 2020-09-23 — — EP disclosed
US-7998974-B2 Fused heterocyclic compounds and their use as sirtuin modulators SIRTRIS PHARMACEUTICALS, INC. (US) 2011-08-16 — — US disclosed
US-7998974-B2 Fused heterocyclic compounds and their use as sirtuin modulators SIRTRIS PHARMACEUTICALS, INC. (US) 2011-08-16 — — US disclosed
EP-2308827-A1 Photocrosslinkable materials Rolic AG (CH) 2011-04-13 — — EP disclosed
US-20100168084-A1 Therapeutic compounds and related methods of use ELIXIR PHARMACEUTICALS, INC. 2010-07-01 — — US disclosed
US-20100168084-A1 Therapeutic compounds and related methods of use ELIXIR PHARMACEUTICALS, INC. 2010-07-01 — — US disclosed
US-20090143376-A1 Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators SITRIS PHARMACEUTICALS, INC. (US) 2009-06-04 — — US disclosed
US-20090143376-A1 Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators SITRIS PHARMACEUTICALS, INC. (US) 2009-06-04 — — US disclosed
EP-1966119-A1 PHOTOCROSSLINKABLE MATERIALS Rolic AG (CH) 2008-09-10 — — EP disclosed
WO-2007071091-A1 PHOTOCROSSLINKABLE MATERIALS ROLIC AG (CH) 2007-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961202-B2 Bis-benzimidazole compounds and methods of using the same HNRNPH1, HNRNPH3, HNRNPUL2 MEN1 1360/4885KMT2A 560/4885RXFP1 4521/4885
US-20090143376-A1 Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators SIRT1, SIRT3, SIRT2 MEN1 4100/4885KMT2A 743/4885RXFP1 1857/4885
US-20190152924-A1 BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME HNRNPH1, HNRNPH3, HNRNPUL2 MEN1 1360/4885KMT2A 560/4885RXFP1 4521/4885
US-20100168084-A1 Therapeutic compounds and related methods of use EP300, KAT2A, KAT6B MEN1 2682/4885KMT2A 422/4885RXFP1 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.